Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist

A compound of Formula I

• or its pharmaceutically acceptable salts, tautomers, stereoisomers, or racemates, wherein:
• A is selected from
• wherein:
• Q is N or CR1;
• R1 is cyano, hydrogen, halogen, C1-6 alkyl, or C1-6 alkoxy;
• R2 is hydrogen or C1-6 alkyl;
• R3 is hydrogen or C1-6 alkyl;
• R4 and R5 are independently hydrogen, halogen, cyano, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C1-6 haloalkyl, or C1-6 haloalkoxy, wherein C1-6 alkyl is optionally substituted with one or more groups selected from C3-6 cycloalkyl and C1-6 alkoxy
• R6 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylhydroxy, C1-6 aminoalkyl, C3-6 cycloalkyl, Y—CO—NH—R13, —Y—Z, or C1-10 heterocyclyl, wherein C1-6 alkyl, C1-6 alkoxy, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 aminoalkyl, C1-6 alkylhydroxy, or C1-10 heterocyclyl is optionally substituted with one or more groups selected from halogen, hydroxyl, amine, C1-6 alkoxy, C3-6 cycloalkyl, C1-6 alkylhydroxy, C1-6 aminoalkyl, C1-6 haloalkoxy, and C1-10 heterocyclyl, wherein C3-6 cycloalkyl or C1-6 aminoalkyl is optionally further substituted with one or more groups independently selected from halogen, hydroxyl, C1-6 alkylhydroxy, —C(O)C1-6 alkyl, —C(O)NH2, and —C(O)—C1-6 alkylhydroxy;
• Y is C1-6 alkyl or C3-6 cycloalkyl;
• Z is —SO2NH2, —SO2CH3, —SOCH3, —SCH3, CH2—NH—(C1-6 alkyl)-SOCH3, —CONH2, —CONH(C1-6 alkyl), —SO2NH(C1-6 alkyl), CON(C1-6 alkyl)2, or —NHCO(C1-6 alkyl);
• R13 is hydrogen, C1-6 alkyl, or C3-6 cycloalkyl;
• R7, R8, R9, and R9a are independently hydrogen, halogen, cyano, C1-6 alkyl, C3-6 cycloalkyl, or C1-6 alkoxy and
• n is 0, 1, or 2.